Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | GAA | P10253 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166884 | 0.83 | ALDH1A1 (0.58) | ALDH1A1GAAMAPTL3MBTL1ALOX15 | |
| SCHEMBL3932937 | 0.83 | ALDH1A1 (0.58) | ALDH1A1GAAMAPTL3MBTL1ALOX15 | |
| SCHEMBL2181959 | 0.78 | ALDH1A1 (0.57) | ALDH1A1GAAMAPTL3MBTL1ALOX15 | |
| SCHEMBL248005 | 0.77 | SMN1; SMN2 (0.43) | ALDH1A1GAAMAPTL3MBTL1ALOX15 | |
| SCHEMBL31139879 | 0.77 | MAPT (0.46) | ALDH1A1GAAMAPTL3MBTL1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10734949 | 0.76 | ALDH1A1 (0.55) | ALDH1A1GAAMAPTL3MBTL1ALOX15 | |
| SCHEMBL11449568 | 0.76 | SMN1; SMN2 (0.41) | ALDH1A1GAAMAPTL3MBTL1ALOX15 | |
| SCHEMBL69313 | 0.75 | GAA (0.71) | ALDH1A1GAAMAPTL3MBTL1ALOX15 | |
| SCHEMBL4264510 | 0.74 | ALDH1A1 (0.49) | ALDH1A1GAAMAPTL3MBTL1ALOX15 | |
| SCHEMBL8288757 | 0.74 | MAPT (0.76) | ALDH1A1GAAMAPTL3MBTL1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4482831-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | Satya Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-118696034-A | Novel bicyclic compounds as RAD51 inhibitors | 萨提亚疗法股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | disclosed |
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | CHRNA7, CHRNA5, CHRNA2 | ALDH1A1 2907/4885GAA 2107/4885MAPT 1038/4885 |
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | RAD51, ERCC4, ERCC2 | ALDH1A1 4307/4885GAA 4761/4885MAPT 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.